.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Dow
Healthtrust
UBS
Fuji
Cipla
QuintilesIMS
Deloitte
Harvard Business School
Farmers Insurance

Generated: November 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,183,295

« Back to Dashboard

Claims for Patent: 8,183,295

Title:Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
Abstract: The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.
Inventor(s): Feldman; David L (Teaneck, NJ), Webb; Randy L (Flemington, NJ)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:12/188,604
Patent Claims: 1. A pharmaceutical composition consisting of (i) 150-500 mg aliskiren or a pharmaceutically acceptable salt thereof, (ii) 1.0-40 mg amlodipine or a pharmaceutically acceptable salt thereof, (iii) 5-200 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers, wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered in combination achieve a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.

2. A pharmaceutical composition according to claim 1, wherein the amount of amlodipine or a pharmaceutically acceptable salt thereof is from 2.5 to 25 mg.

3. A pharmaceutical composition according to claim 2, wherein the amount of hydrochlorothiazide is from 5 to 25 mg.

4. A pharmaceutical composition according to claim 1, wherein the amount of hydrochlorothiazide is from 5 to 25 mg.

5. A pharmaceutical composition consisting of: (i) 150-500 mg aliskiren or a pharmaceutically acceptable salt thereof, (ii) 1.0-40 mg amlodipine or a pharmaceutically acceptable salt thereof, and (iii) 5-200 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers, wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide are administered in a unit dosage form, said combination achieving a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.

6. A pharmaceutical composition consisting of: (i) 140-220 mg aliskiren or a pharmaceutically acceptable salt thereof, (ii) 2.0-12 mg amlodipine or a pharmaceutically acceptable salt thereof, and (iii) 5-15 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers, wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide are administered in a unit dosage form, said combination achieving a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.

7. A pharmaceutical composition consisting of: (i) 550-700 mg aliskiren or a pharmaceutically acceptable salt thereof, (ii) 2.0-12 mg amlodipine or a pharmaceutically acceptable salt thereof, and (iii) 5-30 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers, wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide are administered in a unit dosage form, said combination achieving a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Queensland Health
Federal Trade Commission
AstraZeneca
McKinsey
Mallinckrodt
Accenture
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot